A Phase 1, Open-Label, Parallel-Group Trial Assessing Pharmacokinetics, Safety and Tolerability of the Anti-Human Cytomegalovirus Drug Letermovir in Subjects with Hepatic Impairment

Trial Profile

A Phase 1, Open-Label, Parallel-Group Trial Assessing Pharmacokinetics, Safety and Tolerability of the Anti-Human Cytomegalovirus Drug Letermovir in Subjects with Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Letermovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Jul 2017 New trial record
    • 18 Jul 2017 Results published in the British Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top